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Abstract 
Accumulating evidence has suggested that cooperation of oncogenic activation and 
the host responses is important for cancer development.  In gastric cancer, activation of Wnt 
signaling appears to be a major oncogenic pathway that causes tumorigenesis.  In the chronic 
gastritis caused by Helicobacter pylori infection, cyclooxigenase-2 induces prostaglandin E2 
(PGE2) biosythesis, which plays an important role in tumorigenesis.  We constructed a series 
of mouse models and investigated the role of each pathway in the gastric tumorigenesis.  
Wnt activation in gastric epithelial cells suppresses differentiation, and induces development 
of preneoplastic lesions.  On the other hand, induction of the PGE2 pathway in gastric 
mucosa induces development of spasmolytic polypeptide-expressing metaplasia (SPEM), 
which is a possible preneoplastic metaplasia.  Importantly, simultaneous activation of Wnt 
and PGE2 pathways leads to dysplastic gastric tumor development.  Moreover, induction of 
the PGE2 pathway also promotes gastric hamartoma development when bone morphogenetic 
protein (BMP) signaling is suppressed.  These results indicate that alteration in the Wnt or 
BMP signaling impairs epithelial differentiation, and the PGE2 pathway accelerates tumor 
formation regardless of the types of oncogenic pathways.  We review the phenotypes and 
gene expression profiles of the respective models, and discuss the cooperation of oncogenic 
pathways and host responses in gastric tumorigenesis. 
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Gastric cancer is the second most common cause of cancer-related death worldwide.1  
Infection with Helicobacter pylori is associated with gastric cancer development, and the 
International Agency for Research on Cancer (IARC) classified Helicobacter pylori as a class 
I carcinogen.2  Accumulating evidence has indicated that chronic inflammatory response 
associated with infectious disease is a critical component of tumor development.3  Moreover, 
it has been shown that infections are responsible for more than 15% of all malignant cancers 
worldwide, including the association between H. pylori infection and gastric cancer.4  
Notably, host genetic variants in cytokine genes are related to responsiveness to H. pylori 
infection and the susceptibility to gastric cancer development.5-7  Specific polymorphisms of 
interleukin (IL)-1, an important inflammatory cytokine and a potent inhibitor of gastric acid 
secretion, contribute to intestinal-type gastric cancer progression.8  Polymorphisms in tumor 
necrosis factor (TNF)-, IL-1 receptor antagonist, and IL-10 also influence gastric cancer 
development,8-10 while polymorphisms in the IL-8 promoter have been linked to diffuse-type 
gastric cancer.11  These results suggest that the response of the host cytokine network to H. 
pylori infection is an important factor for gastric cancer development. 
On the other hand, several somatic alterations that activate oncogenic pathways have 
been identified in human gastric cancer.  For example, allelic loss or mutations in p53 are 
detected in 60% or 30-50% of gastric cancers, respectively,12 while mutations in the -catenin 
gene is detected in 30% of the Wnt-activated subgroup of gastric cancer.13  TGF- type II 
receptor gene is recognized as a tumor suppressor, and mutations have been found in gastric 
cancer associated with microsatellite instability (MSI).14,15  Moreover, about 15% of gastric 
cancers show expression of both epidermal growth factor (EGF) and EGF receptor (EGFR), 
 4
suggesting activation of the EGFR signaling pathway.16  Taken together, these results 
indicate that both infection-associated inflammatory responses and oncogenic activation by 
genetic alterations are required for gastric cancer development. 
To date, many genetic mouse models have recapitulated some of the developmental 
stages associated with intestinal-type gastric cancer, such as gastritis, atrophy, mucous cell 
metaplasia, dysplasia, and invasion.17  These models are useful for examining the phenotypic 
changes caused by individual genetic alterations.  In addition to these models, we 
constructed a series of transgenic mouse models to investigate the role of oncogenic and 
inflammatory pathways, such as Wnt, BMP, and PGE2 signaling, in gastric epithelial 
differentiation, inflammation, and tumor development.   
 
Activation of Wnt signaling in gastric mucosa 
 
Wnt activation in human gastric cancer 
Canonical Wnt signaling (Wnt/-catenin signaling) is a critical pathway in the regulation of 
development as well as in tumorigenesis.18  When Wnt signaling is in a resting state, 
cytoplasmic -catenin is phosphorylated by GSK-3 within a complex containing APC and 
Axin, resulting in the degradation of -catenin through the ubiquitin proteasome pathway.19  
When the pathway is activated, the binding of Wnt ligands to Frizzled receptors leads to the 
suppression of the phosphorylation of -catenin, resulting in the to stabilization and nuclear 
translocation of -catenin.  -Catenin then interacts with T-cell factor/lymphocyte enhancer 
factor (TCF/LEF) to induce transcription of Wnt target genes.  In the normal intestine, Wnt 
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signaling is important for maintaining the stem cell characteristics and undifferentiated status 
of the epithelial cells, whereas Wnt signaling is suppressed in the differentiated epithelia (Fig. 
1)19-21  Mutations in the APC or -catenin genes constitutively activate Wnt signaling, which 
causes tumor development in the intestine.22,23  In the gastric mucosa, epithelial cells 
expressing Lgr5, which is a target of Wnt signaling, show stem cell phenotypes, confirming 
the role of Wnt pathway in normal gastric stem cells.24  Moreover, nuclear accumulation of 
-catenin, a hallmark of Wnt signaling activation, is found in 30-50% of gastric cancers (Fig. 
2),13,25-27 and mutations in the -catenin gene have also been detected,13,25,28,29 which suggest 
that activation of Wnt signaling is a major cause of gastric cancer development.  However, 
APC gene mutations are not common in gastric cancer, and -catenin mutations are present in 
fewer than 30% of the Wnt-activated gastric cancers.25   Accordingly, it is possible that 
other mechanism(s) may also activate Wnt signaling in gastric cancer.  For example, it has 
been reported in gastric cancer cells that downregulation of E-cadherin is associated with 
-catenin accumulation in gastric cancer,30 somatic mutations in the ubiquitin ligase -TrCP 
causes stabilization of -catenin,31 and the expression of the SFRP1, 2 and 5 genes encoding 
the secreted endogenous antagonist of the Wnt ligands is silenced by promoter methylation in 
gastric cancer cells.32  All of these alterations contribute to activation of Wnt signaling. 
 
Gastric preneoplastic lesions in K19-Wnt1 transgenic mice 
To examine the role of Wnt signaling in gastric tumorigenesis, we constructed K19-Wnt1 
transgenic mice that express Wnt1, one of the canonical Wnt ligands.27  The K19 gene 
promoter was used to express Wnt1 in gastric epithelial cells, including undifferentiated 
 6
isthmal cells.33,34  The number of undifferentiated epithelial cells that express trefoil factor 2 
(TFF2) increases significantly in the K19-Wnt1 mouse glandular stomach, indicating that Wnt 
signaling functions to maintain the undifferentiated status of the gastric epithelial cells (Fig. 
3a, b).  Notably, aberrant cryptic foci were found on the mucosal surface of K19-Wnt1 mice, 
which consist of dysplastic epithelial cells with irregular branching, and increased cell 
proliferation and -catenin accumulation were also detected (Fig. 3c-g).  We thus diagnosed 
these foci as preneoplastic lesions.  However, gastric tumors do not develop in K19-Wnt1 
mice, indicating that activation of Wnt signaling alone is not sufficient for gastric tumor 
formation.  Importantly, macrophages were infiltrated into the preneoplastic lesions, whereas 
tissue macrophages were sparsely scattered in the normal mucosa of the same mice.  It is 
possible that local inflammatory responses caused by spontaneous physical insult or infection 
might promote proliferation of Wnt-activated dysplastic cells, resulting in formation of the 
preneoplastic lesions.   
 
Induction of PGE2 pathway in gastric mucosa 
 
Induction of COX-2/PGE2 pathway in human gastric cancer 
Epidemiological studies indicate that the regular use of non-steroidal anti-inflammatory drugs 
(NSAIDs) is associated with a decreased incidence of gastric cancer.35-38  NSAIDs inhibit the 
enzymatic activity of cyclooxygenases (COXs), which are rate-limiting enzymes for 
prostaglandin biosynthesis.  COX enzymes catalyze synthesis of prostaglandin (PG)H2, 
which is subsequently converted to various prostanoids, including PGE2, by tissue-specific 
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converting enzymes.  There are two COX isozymes, COX-1 and COX-2, which share a high 
degree of structural and enzymatic homology.  COX-1 is constitutively expressed in most 
tissues and is considered to be responsible for maintaining physiological levels of 
prostaglandin biosynthesis,39 while COX-2 expression is induced by inflammation and in 
tumor tissues by cytokines and growth factors.40-42  Induction of COX-2 is found in 
approximately 70% of gastric cancer, predominantly in intestinal-type gastric cancer, whereas 
COX-1 expression is not elevated.43-45  Moreover, the level of COX-2 expression in gastric 
cancer correlates with the tumor size, depth of invasion and lymph-node metastasis.46-48  
Microsomal PGE synthase-1 (mPGES-1) is an inducible enzyme that converts PGE2 from 
PGH2, and is functionally coupled with COX-2.49  Simultaneous induction of COX-2 and 
mPGES-1 has been observed in a variety of cancers, including gastric cancer, suggesting that 
the inflammatory PGE2 pathway is induced in these tumors (Fig. 1).50-53  Consistently, the 
PGE2 level is found to be significantly increased in gastric cancer47, and the COX-2 and PGE2 
level is associated with the H. pylori infection status,54,55 indicating that H. pylori infection 
causes induction of the PGE2 pathway (Fig. 1).  These results suggest that the COX-2/PGE2 
pathway plays a key role in H. pylori infection-associated inflammation in gastric cancer 
development.   
 
Suppression of gastric cancer by COX-2 inhibition in animal models 
Suppression of gastric tumorigenesis by treatment with COX-2 selective inhibitors (COXIBs) 
has been examined in several animal model experiments.  Growth of gastric cancer cell 
xenografts was inhibited by treatment with COXIBs in immunodeficient mice.56,57  Rat 
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gastric cancer induced by carcinogen N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) and 
mouse gastric tumors induced by H. pylori infection or a combination of H. pylori with 
N-methyl-N-nitrosourea (MNU) were suppressed by treatment with NSAIDs or COXIBs.58-60  
A significant decrease in the PGE2 level and substantial induction of apoptosis were also 
found in the tumors of mice treated with NSAIDs or COXIBs.  H. pylori infection of 
Mongolian gerbils is an established model to study gastric tumorigenesis by H. pylori.  
Treatment of the H. pylori-infected Mongolian gerbils with COXIBs suppressed the 
development of gastric cancer, as well as intestinal metaplasia.61,62, These animal studies 
indicate that the COX-2 pathway plays a key role in gastric tumorigenesis. 
 
Gastric metaplasia in K19-C2mE transgenic mice 
To examine the effect of PGE2 pathway activation in the gastric mucosa, we constructed 
another transgenic mouse model, K19-C2mE, which expresses both COX-2 and mPGES-1 
simultaneously in gastric epithelial cells.34  K19-C2mE mice developed hyperplasia in the 
gastric mucosa, which was suppressed by treatment of the mice with a COX-2 selective 
inhibitor, NS-398 or meloxicam (Fig. 4a, b). 34,63  Histologically, the major cell type 
involved in the hyperplasia were mucous cells, which was similar to the findings in the 
spasmolytic polypeptide/TFF2-expressing metaplasia or SPEM (Fig. 4c, d). 34,64  SPEM is 
characterized by the presence of TFF2 immunoreactive cells, which is morphologically 
similar to those of Brunner’s gland.  Since SPEM was associated with greater than 90% of 
the resected gastric cancers analyzed in three studies,64-66 it is suggested that SPEM is a 
putative preneoplastic metaplasia in the stomach.67  In other animal models, SPEM 
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development was also found in the stomach of Helicobacter-infected mice, gastrin gene 
knockout mice, and in Stat3-activating gp130 mutant mice.68-70  Notably, SPEM in these 
mouse models was accompanied by inflammatory responses.  Importantly, disruption of the 
TNF- gene in K19-C2mE mice results in the suppression of inflammatory responses and 
SPEM development, suggesting that TNF--associated inflammation plays an essential role 
in SPEM formation (Fig. 4e-g).63  In contrast, Rag2 gene disruption did not suppress SPEM 
formation in the K19-C2mE mice, indicating that acquired immune responses are not involved 
in SPEM development. 
Treatment with MNU to the H. pylori-infected mice led to the development of gastric 
tumors.  Notably, multiplicity of gastric tumors induced by H. pylori infection and MNU 
treatment was significantly higher in K19-C2mE mice compared with wild-type mice.71  
These results suggest that PGE2-induced SPEM is a precursor for chemical 
carcinogen-induced gastric tumors. 
 
Oncogenic activation and PGE2 pathway in gastric tumorigenesis 
 
Gastric dysplastic tumors in K19-Wnt1/C2mE transgenic mice 
Compound K19-Wnt1/C2mE transgenic mice were generated by crossing K19-Wnt1 mice and 
K19-C2mE mice, in which both Wnt and PGE2 pathways are activated simultaneously in the 
gastric mucosa.27  K19-Wnt1C2mE mice develop large gastric tumors in the glandular 
stomach (Fig. 5a, b), while no such tumors are found in either simple K19-Wnt1 or 
K19-C2mE transgenic mice.  Histologically, gastric tumors in the K19-Wnt1/C2mE mice 
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(hereafter Gan mice for gastric neoplasia) consist of dysplastic epithelial cells with nuclear 
stratification and irregularly branched tubules (Fig. 5c).  Tumor epithelial cells showed 
increased nuclear accumulation of -catenin and increased Ki-67 labeling, indicating 
promotion of Wnt activity and an increased proliferation of tumor cells, respectively (Fig. 5e).  
Increased capillary vessels were also found in the tumor stroma, which was caused by 
enhanced angiogenesis through the tumor-stroma interaction (Fig. 5f, g).72  Interestingly, 
part of the activated stromal fibroblasts in Gan mouse tumors were derived from bone marrow, 
thus suggesting that the bone marrow cells contribute to the formation of the gastric cancer 
microenvironment. 72   
Notably, TFF2-expressing SPEM was found adjacent to the dysplastic tumor tissue,27 
showing a similar histology to human gastric cancer (Fig. 5h).  K19-C2mE mice start to 
develop SPEM lesions at 5 weeks of age, and the number of TFF-positive metaplastic cells 
increases with age.  In the Gan mouse stomach, the same SPEM phenotype is found at 5 
weeks of age, however, dysplastic tumor cells are also found beginning at 10 weeks of age.  
The number of dysplastic tumor cells then increases with age, leading to formation of gastric 
tumors around 20-30 weeks of age, with SPEM being found adjacent to the tumors.  These 
results, taken together, indicate that the simultaneous activation of the Wnt and PGE2 
pathways causes gastric tumor development through the metaplasia (SPEM)-carcinoma 
sequence.   
 
Gastric hamartomas in K19-Nog/C2mE transgenic mice 
Juvenile polyposis syndrome (JPS) is characterized by hereditary gastrointestinal 
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hamartomatous polyposis,73 and a subset of JPS is caused by germline mutations in the BMP 
receptor type IA gene (BMPR1A).74  BMP signaling through its type I and II receptors leads 
to the phosphorylation of Smad 1,5, and 8, resulting in formation of a complex with Smad4, 
which induces transcription of target genes.75  BMP signaling inhibits epithelial cell 
proliferation and promotes differentiation (Fig. 1), and suppression of BMP signaling in the 
mouse intestine results in JPS-type hamartomatous polyp development,76-78 elongated villi 
and crypt fission.79  Accordingly, it is possible that BMP suppression results in hamartoma 
formation by impairment of epithelial differentiation.  Since the cancer risk in JPS patients 
increases in the gastrointestinal tract,80,81 BMP suppression may also contribute to gastric 
cancer development. 
To examine the effect of BMP suppression in gastric epithelial cells, we next 
constructed K19-Nog mice that express noggin, an endogenous BMP antagonist, in the gastric 
epithelial cells.82  Although BMP signaling was suppressed in the stomach, K19-Nog mice 
do not develop any gastric lesions, and the histology of the gastric mucosa was normal.  To 
examine the effect of cooperation of BMP suppression and PGE2 induction, K19-Nog mice 
and K19-C2mE mice were crossed to construct compound K19-Nog/C2mE mice, in which 
BMP signaling is suppressed and the PGE2 pathway is induced in the gastric mucosa.  
Importantly, the K19-Nog/C2mE mice developed large tumors in the glandular stomach (Fig. 
6a), suggesting that induction of the PGE2 pathway is required for tumor formation in the 
BMP-suppressed gastric mucosa.  Histologically, K19-Nog/C2mE mouse gastric tumors are 
not dysplastic, but consist of irregular branching of the epithelial cell layers, combined with 
the formation of dilated cysts filled with mucin (Fig. 6b, c).  Such histological 
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characteristics are distinct from the dysplastic gastric tumors of Gan mice (Fig. 5c), but are 
typical of the hamartomas of JPS patients.80,81,83  These results indicate that the suppression 
of BMP signaling associated with PGE2 induction causes gastric hamartoma development.   
These results of compound mutant mice indicate that the type of genetic alteration, such 
as Wnt activation or BMP suppression, determines the histological type of tumors, such as 
adenocarcinoma or hamrtoma.84  On the other hand, induction of the PGE2 pathway 
promotes gastric tumor formation regardless of the genetic or histological types.   
 
Gene expression profiles of mouse models and human gastric cancer 
Gan mice and K19-Nog/C2mE mice develop gastric tumors caused by genetic alterations 
similar to those found in human gastric cancer and hamartomas, respectively.  However, it is 
still important to compare gene expression profiles of mouse tumors with those of human 
cancer in order to examine whether these models really recapitulate human gastric tumors.  
We have measured mRNA expression levels using the Affymetrix GeneChip system, which 
includes 21,066 Entrez genes and 5,324 other sequences.85  Genome-scale overview of the 
microarray data revealed that expression changes in the three models, K19-C2mE and 
K19-Wnt1/C2mE (Gan), and K19-Nog/C2mE mice are quite similar, whereas over-expression 
of Wnt1 or Noggin in K19-Wnt1 or K19-Nog mice, respectively, showed expression changes 
in a small portion of genes (Fig. 7a).  These results suggest that most of the expression 
changes in Gan gastric tumors and K19-Nog/C2mE hamartomas are caused by induction of 
PGE2 pathway, rather than by Wnt activation or BMP suppression.  In other words, a small 
number of genes that are upregulated or downregulated by Wnt activation or BMP 
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suppression are important for determining the tumor phenotype. 
Gene expression signatures of human gastric cancer86 and breast cancer87 retrieved 
from the Stanford Microarray Database,88 colon cancer from the NCBI GEO (accession 
GSE5206), and lung tumors90 retrieved from the United States National Cancer Institute 
website91 can be plotted to distinct areas in a 3D figure based on the calculations of principal 
component analysis using the selected genes (Fig. 7b).  Importantly, expression signatures of 
Gan, K19-C2mE, and K19-Nog/C2mE mice are clustered in a similar area as that of human 
gastric cancer, but not to the same area as cancers of other organs.  These results indicate 
that Gan mouse tumors recapitulate human gastric cancer from the molecular etiology to 
histology and gene expression profiles.  It is also possible that most of the changes in gene 
expression in human gastric cancer are attributable to H. pylori infection-associated 
inflammatory responses.  Taken together, these results indicate that the Gan mouse model is 
a useful tool for studying the effects of oncogenic activation and inflammatory responses in 
human gastric cancer development and the evaluation of anti-gastric cancer drugs.  
 
CONCLUSION 
Wnt signaling functions to maintain the undifferentiated status of gastric epithelial cells.  
Activation of Wnt signaling by genetic or epigenetic alteration causes development of 
preneoplastic lesions.  On the other hand, H. pylori infection induces expression of COX-2 
and mPGES-1, resulting in induction of PGE2 biosynthesis.  Induction of the COX-2/PGE2 
pathway is responsible for SPEM development, which is a possible preneoplastic metaplasia 
of gastric cancer.  Importantly, simultaneous induction of Wnt and PGE2 pathways causes 
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development of dysplastic gastric tumors (Fig. 1).  The results of mouse model studies 
reported herein suggest that oncogenic activation, such as activation of Wnt signaling by 
genetic or epigenetic alterations, triggers tumor initiation.  However, initiated epithelial cells 
cannot continue proliferation in the non-inflamed gastric mucosa, thus indicating that Wnt 
signaling alone is not sufficient for tumor development.  In contrast, if the oncogenic 
pathway is activated in the H. pylori-infected (and thus inflamed) stomach, the initiated cells 
proliferate to develop gastric cancer.  Considering the relatively low frequency of somatic 
oncogenic activation, this hypothesis is consistent with the epidemiology of gastric cancer, in 
that only a small minority of the H. pylori-infected population develops gastric cancer, 
although H. pylori infection is an important risk factor for gastric cancer.  It is possible that a 
similar mechanism underlies the development of hamartoma in the BMP-suppressed gastric 
epithelial cells (Fig. 1).  Further studies using these mouse models will be useful for 
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Figure 1  Schematic presentation of the connection of Wnt, BMP, and COX-2/PGE2 
signaling pathways in gastric tumorigenesis.  “Wnt activation” or “BMP suppression” causes 
suppression of epithelial differentiation, which leads to transformation of epithelial cells.  On 
the other hand, H. pylori infection induces expression of COX-2 and mPGES-1, resulting in 
activation of PGE2 signaling pathway.  PGE2 pathway accelerates proliferation of the 
transformed cells through formation of tumor microenvironment. 
 
Figure 2  Nuclear localization of -catenin in human gastric cancer.  (a) Representative 
histological sections of gastric cancer (H&E).  (b) Immunostaining for unphosphorylated 
(active) -catenin in the adjoining section of (a) showing nuclear -catenin accumulation.  
(c) Total -catenin immunostaining in the normal stomach of the same patient showing 
-catenin localization on the cell membrane.  Scale bars, 200 m.  (Reproduced from 
Oshima et al, Gastroenterology 2006; 131: 1086-95 with permission from Elsevier) 
 
Figure 3  Gastric preneoplastic lesions in the K19-Wnt1 mouse stomach.  (a, b) 
TFF2-expressing undifferentiated epithelial cells (asterisks) in the glandular stomach of 
wild-type (a) and K19-Wnt1 mice (b).  Note that the number of TFF2 positive cells was 
increased in the K19-Wnt1mouse.  Scale bars, 200 m.  (c, d) Toluisdine blue staining of 
the whole glandular stomach of wild-type (c) and K19-Wnt1 mice (d).  Arrows in (d) 
indicate preneoplastic lesions.  Scale bars in (c, d), 0.5 mm.  (e-g) Histology of 
preneoplastic lesion (H&E) (e), and Ki-67 staining (f) and -catenin immunostaining (g) of 
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serial sections.  Arrowheads indicate dysplastic epithelial cells.  Scale bars in (e-g), 100 m.  
(Reproduced from Oshima et al, Gastroenterology 2006; 131: 1086-95 with permission from 
Elsevier) 
 
Figure 4  SPEM development in the K19-C2mE mouse stomach.  (a, b) Representative 
photographs of the gastric mucosa of a meloxicam-treated K19-C2mE mouse (a) and a 
no-drug control K19-C2mE mouse (b).  Arrows in (b) indicate hyperplastic lesions.  (c, d) 
Helix pometia lectin staining (c) and TFF2 in situ hybridization (d) of K19-C2mE mouse 
stomach showing expansion of mucous cells expressing TFF2.  Scale bars in (c, d), 200 m.  
(e-g) Suppression of SPEM development in K19-C2mE mice by TNF- gene disruption (e) 
but not by Rag2 knockout (f).  Asterisks and arrows in (f) indicate SPEM and submucosal 
inflammatory infiltration, respectively.  Bar graph indicates the mean mucosal thickness of 
the respective genotypes of mice (g).  Asterisks, P < 0.05.  (Reproduced from Oshima M et 
al, Cancer Res 2005; 65: 9147-51 with permission from American Association for Cancer 
Research, and Oshima H et al, EMBO J 2004; 23: 1669-78 with permission from Nature 
publishing group) 
 
Figure 5  Gastric dysplastic tumors developed in the K19-Wnt1/C2mE (Gan) mice.  (a, b) 
Representative photographs of the gastric mucosa of a Gan mouse (a) and a wild-type 
littermate mouse (b).  Arrowheads indicate gastric tumors.  (c-e) Histology of Gan mouse 
gastric tumors (H&E) (c), and -catenin immunostaining (d) and Ki-67 staining (e) of the 
serial sections.  Scale bars in (c-e), 100 m.  (f, g) Immunostaining for capillary vessels 
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(arrowheads) using anti-vWF antibody in a Gan mouse tumor (f) and a wild-type mouse 
stomach (g).  Note that the number of vessels increased significantly in Gan mouse tumor.  
Scale bars in (f, g), 50 m.  (h) In situ hybridization for TFF2 to detect SPEM (arrows) 
adjacent to the dysplastic tumor area in the Gan mouse stomach.  Scale bars in (h), 200 m.  
(Reproduced from Oshima et al, Gastroenterology 2006; 131: 1086-95 with permission from 
Elsevier, and Guo et al, J Biol Chem 2008; 283: 19864-71) 
 
Figure 6  Gastric hamartomas developed in the K19-Nog/C2mE mice.  (a) Representative 
photograph of a K19-Nog/C2mE mouse gastric tumor (arrows).  (b) Histology of a 
K19-Nog/C2mE gastric tumor showing a hamartomatous cystic structure (H&E).  (c) 
PAS-Alcian blue staining of a K19-Nog/C2mE tumor showing a mucin-containing cystic 
structure.  Scale bars in (b, c), 200 m and 100 m, respectively.  (Reproduced from 
Oshima H et al, Cancer Res 2009; 69: 2729-33 with permission from American Association 
for Cancer Research) 
 
Figure 7  Genome-scale expression pattern of the respective genotype mouse models.  (a) 
Clustered in rows are 5,440 probe sets selected by genes whose expression levels were over 
2-fold greater than the average of wild-type mice.  Genotypes of mice are shown on the top.  
The red-green color scale indicates the log10 ratio of the average of wild-type samples.  Red 
indicates “upregulated”, whereas green indicates “downregulated”.  (b) The overall gene 
expression of human gastric (blue), colon (light blue), breast (green), and lung (red) cancers, 
and K19-C2mE, K19-Wnt1/C2mE (Gan), K19-Nog/C2mE mouse stomach (magenda).  The 
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3D figure was plotted by principal component 1 to 3 calculated using 1,925 genes which were 
altered by more than 2-fold in more than 50 samples.  (Reproduced from Itadani H et al, 
BMC Genomics 2009; 10: 615) 
 







